Phase 3 Trial Evaluating Add-on Tecentriq for Advanced Ovarian Cancer Is Recruiting Participants

Phase 3 Trial Evaluating Add-on Tecentriq for Advanced Ovarian Cancer Is Recruiting Participants
A new Phase 3 trial will evaluate the potential of Tecentriq (atezolizumab) as an add-on therapy to Avastin (bevacizumab) plus chemotherapy in advanced ovarian cancer patients. The trial, called ATALANTE (NCT02891824), was designed to test Tecentriq versus placebo as a maintenance therapy for patients who first responded to platinum-based chemotherapy but relapsed after six months or more. The trial was unveiled June 4 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in a presentation titled “ATALANTE (ENGOT-ov29): A randomized, double-blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab.” Ovarian cancer cells are known to express molecules at their surface that work as “off switches” of the immune system, guarding cancer from attacks. Immunotherapies that target these molecules could, therefore, enhance the responses of ovarian cancer patients. Genentech's Tecentriq binds to one such molecule, called the programmed death-1 (PD-1) receptor. By preventing the ligand PD-L1 from binding to PD-1, the medicine keeps immune cells active and able to fight cancer. Avastin, also developed by Genentech, is a therapy that interferes with the tumor's blood supply, which is key to a tumor’s ability to grow and spread to other parts of the body. Evidence suggests Tecentriq and Avastin act
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *